ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TVAccesswire • 10/20/23
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TVAccesswire • 10/13/23
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TVAccesswire • 10/06/23
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High TemperaturesPRNewsWire • 09/25/23
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by StockholdersPRNewsWire • 09/22/23
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial ResultsPRNewsWire • 08/21/23
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TVAccesswire • 08/11/23
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate PsoriasisPRNewsWire • 07/11/23
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)Accesswire • 06/02/23
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral MucositisPRNewsWire • 05/16/23
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial ResultsPRNewsWire • 05/15/23
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 05/11/23
Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study resultsProactive Investors • 05/04/23
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 05/04/23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's DiseasePRNewsWire • 05/01/23
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 04/24/23
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302PRNewsWire • 04/05/23
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 04/03/23